NovoCureNVCR
NVCR
About: NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Employees: 1,453
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
289% more call options, than puts
Call options by funds: $68.8M | Put options by funds: $17.7M
150% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 5 (+3) [Q4]
88% more capital invested
Capital invested by funds: $1.45B [Q3] → $2.73B (+$1.28B) [Q4]
54% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 35
7% more funds holding
Funds holding: 222 [Q3] → 237 (+15) [Q4]
1.7% less ownership
Funds ownership: 86.3% [Q3] → 84.6% (-1.7%) [Q4]
16% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 77
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$27
46%
upside
Avg. target
$30
60%
upside
High target
$34
83%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
Piper Sandler Jason Bednar 18% 1-year accuracy 7 / 38 met price target | 83%upside $34 | Overweight Maintained | 23 Apr 2025 |
Wedbush David Nierengarten 37% 1-year accuracy 43 / 115 met price target | 46%upside $27 | Neutral Maintained | 16 Apr 2025 |
JP Morgan Jessica Fye 53% 1-year accuracy 20 / 38 met price target | 51%upside $28 | Neutral Maintained | 10 Apr 2025 |
Financial journalist opinion
Based on 11 articles about NVCR published over the past 30 days
Negative
Benzinga
5 hours ago
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025
NovoCure Ltd NVCR reported a first-quarter 2025 loss of 31 cents, down from the 36-cent loss reported a year ago, beating the consensus loss of 46 cents.
Positive
Zacks Investment Research
7 hours ago
NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Neutral
Seeking Alpha
7 hours ago
NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript
NovoCure Limited (NASDAQ:NVCR ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Ingrid Goldberg - IR Bill Doyle - Executive Chairman Ashley Cordova - CEO Christoph Brackmann - CFO Frank Leonard - EVP and President, NovoCure Oncology Nicolas Leupin - CMO Conference Call Participants Larry Biegelsen - Wells Fargo Jason Bednar - Piper Sandler Vijay Kumar - Evercore ISI Jessica Fye - JPMorgan Emily Bodnar - H.C. Wainwright Operator Good day, and thank you for standing by.
Positive
The Motley Fool
8 hours ago
NovoCure Surpasses Q1 Expectations
NovoCure (NVCR 7.15%), a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, released its first-quarter results on April 24, 2025. The company reported notable gains with revenue rising to $155 million (GAAP) in Q1 2025, surpassing Wall Street's estimate of $146 million.
Negative
Zacks Investment Research
8 hours ago
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
NovoCure (NVCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.36 per share a year ago.
Neutral
Business Wire
11 hours ago
Novocure Reports First Quarter 2025 Financial Results
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the first quarter ended March 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “This is a period of meaningful momentum for Novocure,” said Ashley Cordova, CEO Novocure. “After years in a single commercial indication, our footprint is ex.
Neutral
Business Wire
1 day ago
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 in Chicago. The PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advance.
Neutral
Business Wire
2 days ago
Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) concurrently with immune checkpoint inhibitors or docetaxel who have progressed on or after a platinum-based regimen. “Optune Lua is an innovative and urgently needed new approach for treating metastatic non-small cell lung cancer,” said Joachim Aerts, M.D., a LUNAR inves.
Positive
Zacks Investment Research
1 week ago
NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
The Motley Fool
1 week ago
Why NovoCure Stock Was Withering on Wednesday
Cancer-focused biotech NovoCure (NVCR -4.46%) was the focus of a stock price target cut on Wednesday, and investors weren't particularly happy about it.
Charts implemented using Lightweight Charts™